**Online-Only Supplements**

**eMethods 1: Case Definitions**

**PIMS-TS/MIS(-C)**

Recognized case definitions for the novel pediatric multisystem inflammatory syndrome, related to coronavirus disease 2019 (COVID-19).

|  |  |
| --- | --- |
| **Source** | **Case definition** |
| **PIMS-TS (RCPCH)**1 | 1. A child presenting with persistent fever, inflammation (neutrophilia, elevated CRP and lymphopaenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features. This may include children fulfilling full or partial criteria for Kawasaki disease.
2. Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice).
3. SARS-CoV-2 PCR testing may be positive or negative
 |
| **MIS-C (CDC)**2 | 1. Age <21 years
2. Clinical presentation consistent with MIS-C, including all of the following:
	* Fever
		+ Documented fever >38.0°C (100.4°F) for ≥24 hours or
		+ Report of subjective fever lasting ≥24 hours
	* Laboratory evidence of inflammation
	* Severe illness requiring hospitalization
	* Multisystem involvement
		+ 2 or more organ systems involved
			- Cardiovascular (eg, shock, elevated troponin, elevated BNP, abnormal echocardiogram, arrhythmia)
			- Respiratory (eg, pneumonia, ARDS, pulmonary embolism)
			- Renal (eg, AKI, renal failure)
			- Neurologic (eg, seizure, stroke, aseptic meningitis)
			- Hematologic (eg, coagulopathy)
			- Gastrointestinal (eg, elevated liver enzymes, diarrhea, ileus, gastrointestinal bleeding)
			- Dermatologic (eg, erythroderma, mucositis, other rash)
3. No alternative plausible diagnoses
4. Recent or current SARS-CoV-2 infection or exposure
	* Any of the following:
		+ Positive SARS-CoV-2 RT-PCR
		+ Positive serology
		+ Positive antigen test
		+ COVID-19 exposure within the 4 weeks prior to the onset of symptoms
 |
| **MIS (WHO)**3 | All 6 criteria must be met:1. Age 0 to 19 years
2. Fever for ≥3 days
3. Clinical signs of multisystem involvement (at least 2 of the following):
	* Rash, bilateral nonpurulent conjunctivitis, or mucocutaneous inflammation signs (oral, hands, or feet)
	* Hypotension or shock
	* Cardiac dysfunction, pericarditis, valvulitis, or coronary abnormalities (including echocardiographic findings or elevated troponin/BNP)
	* Evidence of coagulopathy (prolonged PT or PTT; elevated D-dimer)
	* Acute gastrointestinal symptoms (diarrhea, vomiting, or abdominal pain)
4. Elevated markers of inflammation (eg, ESR, CRP, or procalcitonin)
5. No other obvious microbial cause of inflammation, including bacterial sepsis and staphylococcal/streptococcal toxic shock syndromes
6. Evidence of SARS-CoV-2 infection
	* Any of the following:
		+ Positive SARS-CoV-2 RT-PCR
		+ Positive serology
		+ Positive antigen test
		+ Contact with an individual with COVID-19
 |

**Kawasaki disease (KD)**

|  |  |
| --- | --- |
| **Source** | **Case definition** |
| **Classic KD**4 | Classic KD is diagnosed in the presence of fever for at least 5 d (the day of fever onset is taken to be the first day of fever) together with at least 4 of the 5 following principal clinical features. In the presence of ≥4 principal clinical features, particularly when redness and swelling of the hands and feet are present, the diagnosis of KD can be made with 4 d of fever, although experienced clinicians who have treated many patients with KD may establish the diagnosis with 3 d of fever in rare cases:1. Erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa
2. Bilateral bulbar conjunctival injection without exudate
3. Rash: maculopapular, diffuse erythroderma, or erythema multiforme-like
4. Erythema and edema of the hands and feet in acute phase and/or periungual desquamation in subacute phase
5. Cervical lymphadenopathy (≥1.5 cm diameter), usually unilateral

A careful history may reveal that ≥1 principal clinical features were present during the illness but resolved by the time of presentation.Patients who lack full clinical features of classic KD are often evaluated for incomplete KD (Figure 3). If coronary artery abnormalities are detected, the diagnosis of KD is considered confirmed in most cases.Laboratory tests typically reveal normal or elevated white blood cell count with neutrophil predominance and elevated acute phase reactants such as C-reactive protein and erythrocyte sedimentation rate during the acute phase. Low serum sodium and albumin levels, elevated serum liver enzymes, and sterile pyuria can be present. In the second week after fever onset, thrombocytosis is common. |
| **Incomplete KD**4 | Children with fever ≥5 days and 2 or 3 compatible clinical criteria of KD OR infants with fever for ≥7 days without other explanation and:1. Three or more laboratory findings
	1. Anemia for age
	2. Platelet count of ≥450,000 after the 7th day of fever
	3. Albumin <3.0 g/dl
	4. Elevated ALT level
	5. WBC count of ≥15,000/mm³
	6. Urine ≥10 WBC/hpf

OR1. Positive echocardiogram (z-score of LAD or RAD ≥2.5, coronary artery aneurysm or ≥3 suggestive features including decreased left ventricular function, mitral regurgitation, pericardial effusion, or Z scores in left anterior descending coronary artery or right coronary artery of 2 to 2.5).
 |

**eMethods 2: Search Strategy Criteria**

|  |
| --- |
| **Inclusion criteria**1. Study population: hyperinflammatory syndrome meeting the case definitions of PIMS-TS1 or MIS(-C)2,3 in children (0-19 years of age) with a temporal association with confirmed or probable COVID-19
2. Outcome: clinical, epidemiological and immunological descriptions, therapeutic management and clinical effect, and prognosis of individuals or cohorts of patients.
3. Types of study designs: RCT, observational studies, case-control studies, cross-sectional studies, case reports and case series

**Exclusion criteria**1. Studies on adult patients with SARS-CoV-2 infection and/or SARS-CoV-2 associated hyperinflammatory syndromes
2. Studies on pediatric patients with other coronavirus infections (SARS-CoV-1 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection or other respiratory infections.
3. Studies with incomplete or lacking necessary data
4. Duplicate studies
5. Studies without accessible full text versions
6. Studies not in English language
 |

**eTable 1: Risk of Bias Assessment on Included Case Series and Cohort Studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Selection** | **Comparability** | **Outcome** | **Total** |
|  | *Representativeness of the exposed cohort* | *Selection of non-exposed cohort*  | *Ascertainment of exposure* | *Demonstration that outcome of interest was not present at start of study* | *Comparability of cohorts on the basis of the design or analysis* | *Assessment of outcome* | *Was follow-up long enough for outcomes to occur* | *Adequacy of follow up of cohorts* | *Overall risk of bias score (max = 9)* |
|  | a) truly representative of the average PIMS/MIS in the community \*b) somewhat representative of the average PIMS/MIS in the community \*c) selected group of users eg nurses, volunteersd) no description of the derivation of the cohort | a) drawn from the same community as the exposed cohort \*b) drawn from a different sourcec) no description of the derivation of the non exposed cohort | a) secure record (eg surgical records) \*b) structured interview \*c) written self reportd) no description | a) yes \*b) no | a) study controls for clinical presentation \*b) study controls for unfavorable outcome \* | a) independent blind assessment \*b) record linkage \*c) self reportd) no description | a) yes (full period of hospitalisation + 4 weeks after discharge) \*b) no | a) complete follow up - all subjects accounted for \*b) subjects lost to follow up unlikely to introduce bias - small number lost - > 75% follow up, or description provided of those lost) \*c) follow up rate < 75 % (select an adequate %) and no description of those lostd) no statement |
| Belhadjer Z. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | c) | 4 |
| Dallan C. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Licciardi F. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Riphagen S. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Waltuch T. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Chiotos K. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | c) | 4 |
| Miller J. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Grimaud M. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Toubiana J. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Verdoni L. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | c) | 4 |
| Whittaker E. et al. | a)\* | a)\* | a)\* | a)\* | a)\* | b)\* | b) | d) | 6 |
| Cheung E. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Blondiaux E. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 3 |
| Pouletty M. et al | a)\* | a)\* | a)\* | a)\* | a)\* + b)\* | b)\* | b) | c) | 7 |
| Ramcharan T. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | c) | 4 |
| Capone C. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Kaushik S. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Joshi K. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Foong Ng K. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Hameed S. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Riollano-Cruz M. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Feldstein L. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |
| Dufort E. et al. | a)\* | c) | a)\* | a)\* |  | b)\* | b) | d) | 4 |

**eMethods 3: Code availability**

Code, additional supporting data and full data analysis can be found at <https://github.com/rmvpaeme/PIMS_MISC_SR>. All raw data will be made available after peer review. The processed data can be found as supplementary data with this manuscript.

**Reference list of supplementary materials**

1. Royal College of Health Paediatrics and Child (RCPCH). Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem- inflammatory syndrome-20200501.pdf. Published 2020. Accessed July 8, 2020.

2. CDC. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19), 2020. https://emergency.cdc.gov/han/2020/han00432.asp.

3. World Health Organization (WHO). Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020;(May):1-3.

4. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*. 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484